Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

Shimizu, Tomohiro; Arita, Kosuke; Murota, Eihiro; Hiratsuka, Shigeto; Fujita, Ryo; Ishizu, Hotaka; Asano, Tsuyoshi; Takahashi, Daisuke; Takahata, Masahiko; Iwasaki, Norimasa

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

Shimizu, Tomohiro; Arita, Kosuke; Murota, Eihiro et al.

Journal of Bone and Mineral Metabolism, 2021, 39(5), 868-875

Permalink : https://hdl.handle.net/2115/86683

このアイテムのアクセス数:498件（2026-08-12 09:11 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
J Bone Miner Metab 39 868-875	pdf	3.15 MB	450

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/86683
タイトル	Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
著者	Shimizu, Tomohiro ; Arita, Kosuke ; Murota, Eihiro ; Hiratsuka, Shigeto ; Fujita, Ryo ; Ishizu, Hotaka ; Asano, Tsuyoshi ; Takahashi, Daisuke ; Takahata, Masahiko ; Iwasaki, Norimasa
e-Rad_Researcher 60784246 著者名 Shimizu, Tomohiro
著者名 Arita, Kosuke
著者名 Murota, Eihiro
著者名 Hiratsuka, Shigeto
著者名 Fujita, Ryo
著者名 Ishizu, Hotaka
著者名 Asano, Tsuyoshi
著者名 Takahashi, Daisuke
e-Rad_Researcher 40374368 著者名 Takahata, Masahiko
e-Rad_Researcher 30322803 著者名 Iwasaki, Norimasa
言語	英語
キーワード	Postmenopausal osteoporosis
	Romosozumab
	Denosumab
	Bone metabolic marker
発行日	2021-09
出版者	Springer
収録物名	Journal of Bone and Mineral Metabolism
巻(号)	39(5)
ページ	868-875
抄録	Purpose We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Methods Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or DENO from BP/naive or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated. Results ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months. Conclusions ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a post-peer-review, pre-copyedit version of an article published in Journal of Bone and Mineral Metabolism. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00774-021-01226-1
PISSN	0914-8779
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00774-021-01226-1